This article reports the clinical pharmacist's involvement in managing a case of recurrent/refractory Burkitt lymphoma (R/R BL) treated with glofitamab. After the initial infusion, the patient developed cytokine release syndrome (CRS). Following physician-pharmacist consultation and evaluation, tocilizumab was administered to mitigate cytokine storm and albumin expansion, along with electrolyte replacement, antipyretics, and anti-infective therapy. Subsequent administration of immunological cell-related neurotoxicity syndrome triggered diazepam for seizure control and glucocorticoids, supplemented by blood pressure reduction and oxygen therapy. The pharmacist provided pharmacological recommendations regarding fever, infections, and seizures during treatment, which the physician subsequently adopted. As there are currently no domestic reports on pediatric cases using glofitamab for R/R BL, this case study offers valuable insights for rational drug use in pediatric patients and demonstrates effective pharmacological monitoring during immunotherapy.

1.Sommelet D, Lacour B, Clavel J. Epidémiologie des cancers de l'enfant[J]. Bull Acad Natl Med, 2003, 187(4): 711-741. https://pubmed.ncbi.nlm.nih.gov/14556478/.

2.Roschewski M, Staudt LM, Wilson WH. Burkitt's lymphoma[J]. N Engl J Med, 2022, 387(12): 1111-1122. DOI: 10.1056/NEJMra2025746.

3.Cairo M, Auperin A, Perkins SL, et al. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group[J]. Br J Haematol, 2018, 182(6): 859-869. DOI: 10.1111/bjh.15491.

4.Short NJ, Kantarjian HM, Ko H, et al. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma[J]. Am J Hematol, 2017, 92(6): E114-E117. DOI: 10.1002/ajh.24720.

5.Pinto E, Lione L, Compagnone M, et al. From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy[J]. J Transl Med, 2025, 23(1): 10. DOI: 10.1186/s12967-024-06052-3.

6.Samples L, Sadrzadeh H, Frigault MJ, et al. Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma[J]. Blood, 2025, 145(23): 2762-2767. DOI: 10.1182/blood.2024026831.

7.Burkhardt B, Rossato G, Dixon M, et al. A phase I/II trial to evaluate the safety, pharmacokinetics, and efficacy of glofitamab as monotherapy and in combination with R-ICE chemoimmunotherapy in children and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma (iMATRIX-GLO) [J]. Blood, 2023, 142(S1): 3096-3096. https://doi.org/10.1182/blood-2023-174929.

8.Colin MV, Vinti L, Simon SRA, et al. Glofitamab plus R-ICE or as monotherapy in children and adolescents with relapsed/refractory B-cell non-Hodgkin lymphoma: updated analysis from the iMATRIX-GLO study[J]. Hematologic Oncol, 2025, 43(S3): e33_70093-e33_70093. https://doi.org/10.1002/hon.70093_33.

9.Rosolen A, Perkins SL, Pinkerton CR, et al. Revised international pediatric non-Hodgkin lymphoma staging system[J]. J Clin Oncol, 2015, 33(18): 2112-2118. DOI: 10.1200/JCO.2014.59.7203.

10.国家卫生健康委员会委员会. 学龄儿童青少年超重与肥胖筛查: WS/T 586-2018[S]. 2018.

11.Matson KL, Horton ER, Capino AC, et al. Medication dosage in overweight and obese children[J]. J Pediatr Pharmacol Ther, 2017, 22(1): 81-83. DOI: 10.5863/1551-6776-22.1.81.

12.Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update[J]. J Clin Oncol, 2021, 39(18): 2037-2048. DOI: 10.1200/JCO.21.00471.

13.Bacac M, Colombetti S, Herter S, et al. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies[J]. Clin Cancer Res, 2018, 24(19): 4785-4797. DOI: 10.1158/1078-0432.CCR-18-0455.

14.Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells[J]. Biol Blood Marrow Transplant, 2019, 25(4): 625-638. DOI: 10.1016/j.bbmt.2018.12.758.

15.中国研究型医院学会生物治疗学专委会. CAR T细胞治疗NHL毒副作用临床管理专家共识[J].转化医学杂志, 2021, 10(1): 1-11. [Specialty Committee of Biotherapy, the Chinese Research Hospital Association. Experts consensuson clinical management of toxicity associated with CAR T cell therapy in non-Hodgkin's lymphoma(NHL)[J]. Translational Medicine Journal, 2021, 10(1): 1-11.] DOI: 10.3969 /j.issn.2095-3097.2021.01.001.

16.Phillips TJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab in relapsed/refractory mantle cell lymphoma: results from a phase I/II study[J]. J Clin Oncol, 2025, 43(3): 318-328. DOI: 10.1200/JCO.23.02470.

17.Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells[J]. Nat Med, 2018, 24(6): 739-748. DOI: 10.1038/s41591-018-0036-4.

18.Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J]. N Engl J Med, 2013, 368(16): 1509-1518. DOI: 10.1056/NEJMoa1215134.

19.Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia[J]. N Engl J Med, 2018, 378(5): 449-459. DOI: 10.1056/NEJMoa1709919.

20.Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia[J]. Haematologica, 2013, 98(12): 1826-1835. DOI: 10.3324/haematol.2013.091025.

21.Averbuch D, Cordonnier C, Livermore DM, et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)[J]. Haematologica, 2013, 98(12): 1836-1847. DOI: 10.3324/haematol.2013.091330.

22.Maschmeyer G, De Greef J, Mellinghoff SC, et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)[J]. Leukemia, 2019, 33(4): 844-862. DOI: 10.1038/s41375-019-0388-x.

23.中华医学会血液学分会, 中国医师协会血液科医师分会. 中国中性粒细胞缺乏伴发热患者抗菌药物临床应用指南（2020年版）[J]. 中华血液学杂志, 2020, 41(12): 969-978. [Chinese Society of Hematology, Chinese Medical Association, Chinese Medical Doctor Association, Hematology Branch.Chinese guidelines for the clinical application of antibacterial drugs for agranulocytosis with fever (2020)[J]. Chinese Journal of Hematology, 2020, 41(12): 969-978.] DOI: 10.3760/cma.j.issn.0253-2727.2020.12.001.

24.Lehrnbecher T, Fisher BT, Phillips B, et al. Guideline for antibacteria prophylaxis administration in pediatric cancer and hematopoietic stem cell transplantation[J]. Clin Infect Dis, 2020, 71(1): 226-236. DOI: 10.1093/cid/ciz1082.

25.John SB, Ralph EK, Dainius AB, et al. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin[J]. Pediatrics, 2014, 134(1): e146-e153. DOI: 10.1542/peds.2013-3636.

26.Anthony JG, Heather RD, Heather F, et al. Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis[J]. Clin infect Dis, 2018, 67(11): 1777-1780. DOI: 10.1093/cid/ciy416.

27.刘小会, 毕晶, 张亚芳, 等. 左氧氟沙星在儿科临床中的应用 [J]. 中华实用儿科临床杂志, 2023, 38(10): 764-767. [Liu XH, Bi J, Zhang YF, et al. Application status and safety of levofloxacin in pediatric clinical practice[J]. Chinese Journal of Applied Clinical Pediatrics, 2023, 38(10): 764-767.] DOI: 10.3760/cma.j.cn101070-20230627-00527.

28.伍俊妍, 孙树梅. 氟喹诺酮类抗菌药物在儿童应用中的专家共识[J]. 今日药学, 2018, 28(1): 1-10. DOI: 10.12048/j.issn.1674-229X.2018.01.001.

29.US Department of Health and Human Services. Common Terminology Criteria for Adverse Events v4.0 (CTCAE)[R/OL]. (2017-07-20) [2025-02-10]. https://ctep.cancer.gov/protocol/Development/electronic_applications/ctc.

30.中华医学会血液学分会白血病淋巴瘤学组,中国抗癌协会血液肿瘤专业委员会造血干细胞移植与细胞免疫治疗学组. 嵌合抗原受体T细胞治疗相关神经系统毒副反应管理中国专家共识（2022年版）[J].中华血液学杂志, 2022,43(2):96-101. [Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association Group of Hematopoietic Stem Cell Transplantation and Cellular Therapy, Hematological Oncology Committee of China Anti-Cancer Association. Consensus of Chinese experts on the clinical management of chimeric antigen receptor T-cell-associated neurotoxicity (2022)[J]. Chinese Journal of Hematology, 2022, 43(2): 96-101.] DOI: 10.3760/cma.j.issn.0253-2727.2022.02.002.

31.Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management[J]. Blood Rev, 2019, 34: 45-55. DOI: 10.1016/j.blre.2018.11.002.

32.Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome[J]. Blood, 2014, 124(2): 188-195. DOI: 10.1182/blood-2014-05-552729.